Telomir Pharmaceuticals (NASDAQ: TELO) announced the closing of its acquisition of TELI Pharmaceuticals, Inc., a strategic move that establishes the company as the sole global rights holder of Telomir-1 (Telomir-Zn) and eliminates prior geographic fragmentation of the asset. The transaction, approved by shareholders in March, includes $1.0 million in funding at closing and up to an additional $4.0 million in milestone-based contributions tied to clinical development progress.
The acquisition strengthens Telomir’s position as it advances Telomir-Zn toward the clinic following a recent Investigational New Drug (IND) submission for the treatment of advanced and metastatic triple-negative breast cancer. The company plans to initiate a Phase 1/2 trial upon regulatory clearance while retaining flexibility for potential global partnerships.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company’s lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
For more details, the full press release is available at https://ibn.fm/DcY4o.
This consolidation is significant because it removes previous barriers to global development and commercialization of Telomir-1. By securing worldwide rights, Telomir can now streamline its regulatory strategy and potentially negotiate more favorable partnerships without territorial restrictions. The additional milestone-based funding also provides financial support for upcoming clinical trials.
The focus on triple-negative breast cancer is particularly notable, as this aggressive form of cancer has limited treatment options and a poor prognosis. Telomir-1’s mechanism of action, targeting epigenetic and metabolic pathways, offers a novel approach that could differentiate it from existing therapies. If successful, the drug may not only address an unmet medical need but also validate the company’s platform for other indications.
Investors and industry observers will be watching for updates on the Phase 1/2 trial initiation and any partnership announcements. The company’s ability to execute on its clinical development plan will be critical in determining the value of Telomir-1 and the company’s future prospects.
For the latest news and updates relating to TELO, visit the company’s newsroom at https://ibn.fm/TELO.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Telomir Pharmaceuticals Acquires TELI, Secures Global Rights to Lead Drug Telomir-1.